Work

HER2 and Folate Receptor Targeted Therapy is Enhanced by NK Cell-Activating Cytokines

Year: 2013
Type: article
Abstract: The anti-tumor effects of therapeutic monoclonal antibodies (mAb) may depend on immune effector cells that express Fc receptors (FcR) for immunoglobulin G. Natural killer (NK) cells are innate immune effector cells that play a crucial role in cancer rejection and immunosurveillance.Importantly NK cells express the Fcγ receptor IIIa (FcγRIIIa) and various cytokine receptors, which can be activated upon encountering antibody-coated targets and cytokines in the tumor microenvironment.Previous work from our group reported a significant association between elevated IFN-γ levels in patients receiving Trastuzumab plus the cytokine interleukin-12 (IL-12) and more favorable outcomes in phase I clinical trials.We hypothesized that co-administration of IL-12 with an anti-HER2 mAb (4D5) would enhance the FcR-dependent immune mechanisms and IFN-γ production and contribute to its anti-tumor activity.We aimed to elucidate the cell type responsible for this elevated IFN-γ production and further determine how this subset affected combination therapy.Treatment with IL-12 and 4D5 significantly inhibited the growth of CT-26 HER2 , a murine cancer cell line that expresses human HER2.Combination therapy was associated with increased circulating levels of IFN-γ, MIG and RANTES.IFN-γ-deficient mice demonstrated that this cytokine was necessary for the observed anti-tumor effects of therapy with IL-12 plus 4D5.Dual therapy induced tumor necrosis and depletion studies confirmed that NK cells mediated the anti-tumor effects of this treatment combination.
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W2526782094
FWCI:
Cites: 166
Cited by:
Related to: 10